LONDON (AP) Drug maker Pfizer sweetened its takeover offer for U.K.-based AstraZeneca on Friday and outlined measures it hopes will ease British government concerns over the deal.
The Viagra maker said it is offering 50 pounds ($84) a share in cash and stock, a 7.3 increase on the previous bid. The offer values AstraZeneca at $106 billion.
"There is a highly compelling strategic, business and financial rationale for combining our businesses, with significant benefits for shareholders and stakeholders of both companies," Pfizer CEO Ian Read said in a statement announcing the offer.
AstraZeneca, which had shot down earlier takeover attempts, replied in a statement that its board would meet to discuss the latest offer.
Pfizer also sent a letter to Prime Minister David Cameron, promising to keep the country's corporate and tax residence in England and saying the "golden triangle of Oxford, Cambridge and London would represent a vital component" of the deal.
Critics fear the takeover could mean big job losses, and the potential loss of stature in the science sector in Britain has become a political issue.
"This does look a little bit like a transaction which has tax planning as a rationale," the opposition Labour Party's shadow business secretary, Chuka Umunna, told the BBC.
Pfizer Inc. is the world's second-biggest drugmaker by revenue while AstraZeneca PLC ranks eighth. AstraZeneca was created in 1999 through the merger of Sweden's Astra and Britain's Zeneca.
- Mergers, Acquisitions & Takeovers
- Investment & Company Information
- AstraZeneca
- Pfizer
RESULT
Determined Amgen sweetens its bid for Onyx Pharma. August 6, 2013 | By John Carroll. Share. Pfizer, AstraZeneca back a new strategy for cancer drug
Novartis sweetens investors with $5 billion share buyback ...
Live: Fed meeting, GDP, job numbers this week; Pfizer's bid for AstraZeneca; U.S. plans to hit Putin's inner circle with new sanctions; Pfizer chasing AstraZeneca for
Sweden sweetens offer in bid to win Brazil fighter jet ...
Sweden sweetens offer in bid to win Brazil fighter jet deal. Published: 18 Sep 2009 07:25 GMT+02:00 Updated: US drug giant Pfizer confirms AstraZeneca bid.
Merz | cafepharma
Valeant sweetens bid for Obagi Pfizer; Razadyne; Roche; News. The Abbott Laboratories Amgen Arena Pharmaceuticals AstraZeneca Bayer Biogen Idec biotech Boston
Obagi Medical Products | cafepharma
Obagi Bidding War Seen Pharmaceuticals; Valeant sweetens bid for Pharmaceuticals AstraZeneca Bayer Biogen Idec biotech Boston Scientific Bristol
Dish Sweetens Bid for Clearwire, Topping Rival Sprint ...
Pharma Pact? U.S pharma giant Pfizer has reportedly approached British rival AstraZeneca to propose a $101 billion takeover.
One Suitor Sweetens Bid for Huntsman - New York Times
One Suitor Sweetens Bid for Huntsman Sign In to E-Mail or Save This; Print; Reprints; By REUTERS. Published: July 10, 2007. Pfizer Move for AstraZeneca
In Insider and Enron Cases, Balancing Lies and Thievery ...
Insight, Adding a New Partner, Sweetens Bid for Quest Software In the News. Mergers & Acquisitions Pfizer Move for AstraZeneca Seen. Most Viewed. 1.
Sprint Sweetens Buyout Offer for Clearwire Ahead of Vote
Sprint Sweetens Buyout Offer for Clearwire Ahead of Vote. Reuters With CNBC.com Tuesday, 21 May 2013 Pfizer considers $100B bid for AstraZeneca: report
Glencore Sweetens Bid for Xstrata as Merger Descends into ...
Pfizer 'Held' Talks for $100bn Takeover of AstraZeneca; Glencore Sweetens Bid for Xstrata as Merger Descends into Chaos.
